Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the clinical screening cooperative group of the European organization for research and treatment of cancer

Journal of Clinical Oncology

Volumn 13, Issue 2, 1995, Pages 314-322

  Chevallier, Bernard ^a   Fumoleau, Pierre ^b   Kerbrat, Pierre ^b   Dieras, Veronique ^b   Roche, Henri ^b   Krakowski, Ivan ^b   Azli, Nacer ^b   Bayssas, Martine ^b   Lentz, Marie Ange ^b   Van Glabbeke, Martine ^b  

^a CENTRE HENRI BECQUEREL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PREDNISONE;

ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; FLUID RETENTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CONFIDENCE INTERVALS; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PACLITAXEL; QUALITY CONTROL; TAXOIDS; TIME FACTORS;

EID: 0028837396     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.2.314     Document Type: Article

References (35)

1. Peto R: Treatment of Early Breast Cancer. Early Breast Cancer Trialists' Collaborative Group, vol 1. Oxford, United Kingdom, Oxford Medical Publication, 1991
2. Henderson IC: Chemotherapy of breast cancer. Cancer 51:2553-2559, 1983
3. Henderson IC: Chemotherapy of advanced disease, in Harris AL Jr, Henderson IC, Hellman S, et al (eds): Breast Disease. Philadelphia, PA, Lippincott, 1987, pp 428-479
4. French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6:679-688, 1988
5. French Epirubicin Study Group: A prospective randomized trial comparing epirubicin monotherapy to fluorouracil, cyclophosphamide and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 9:305-312, 1991
6. Chlebowski RT, Smalley RV, Veiner JM, et al: Combination versus sequential single agent chemotherapy in advanced breast cancer: Associations with metastatic sites and long term survival. Br J Cancer 59:227-230, 1989
7. Antmann K, Souhami RL: High dose chemotherapy in solid tumors. Ann Oncol 4:S29-S44, 1993 (suppl)
8. Ahmann DL, Schaid DJ, Bisel HF, et al: The effect on survival of initial chemotherapy in advanced breast cancer: Polychemotherapy versus single drug. J Clin Oncol 5:1928-1932, 1987
9. Wani MC, Taylor HL, Wall ME, et al: Plant antitumour agents VI. The isolation and structure of Taxol, a novel antileukemic and antitumour agent from Taxus brevifolia. J Am Chem Soc 93:2325-2337, 1971
10. McGuire WP, Rowinski EK, Rosenhein NB, et al: Taxol, a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
11. Bissery MC, Guenard D, Gueritte Voegelein F, et al: Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analog. Cancer Res 51:4845-4852, 1991
12. Ringel I, Horwitz SB: Studies with RP 56976 (Taxotere, docetaxel): A semi synthetic analog of Taxol. J Natl Cancer Inst 83:288-291, 1991
13. Extra JM, Rousseau F, Bruno R, et al: Phase I and pharmacokinetic study of Taxotere (docetaxel) (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037-1042, 1993
14. Bisset D, Setanoians A, Cassidy J, et al: Phase I and pharmacokinetic study of Taxotere (docetaxel) (RP 56976) administered as a 24 hour infusion. Cancer Res 53:523-527, 1993
15. Pazdur R, Newman RA, Newman BM, et al: Phase I trial of Taxotere (docetaxel): Five day schedule. J Natl Cancer Inst 84:1781-1788, 1992
16. Burris HA, Irvin R, Kuhn J, et al: Phase I clinical trial of Taxotere (docetaxel) given as either a 2-hour or 6-hour infusion. J Clin Oncol 11:950-958, 1993
17. De Valeriola D, Brassinne C, Piccart M, et al: Phase I pharmacokinetic study of Taxotere (docetaxel) (RP 56076) administered as a weekly infusion. Proc Am Assoc Cancer Res 33:1563, 1992 (abstr)
18. Miller A, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
19. Kaplan E, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-471, 1958
20. Ahmann DL, Bisel HF, Hagan RT, et al: Controlled evaluation of Adriamycin in patients with disseminated breast cancer. Cancer Chemother Rep 58:877-881, 1974
21. Fumoleau P, Delgado FM, Delozier T, et al: Phase II trial of weekly intravenous vinorelbine in first line advanced breast cancer chemotherapy. J Clin Oncol 11:1245-1252, 1993
22. Trudeau ME, Eisenhauer E, Lofters W, et al: Phase II study of Taxotere (docetaxel) as first line chemotherapy for metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group (NCI CTG) study. Proc Am Soc Clin Oncol 12:59, 1993 (abstr)
23. Seidman AD, Hudis C, Crown JPA, et al: Phase II evaluation of Taxotere (docetaxel) (RP 56976; NSC 628503) as initial chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 12:52, 1993 (abstr)
24. Ten Bokkel Huinink WW, Prove AM, Piccart M, et al: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 5:527-532, 1994
25. Holmes FA, Walters RS, Theriault HL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
26. Nabholtz JM, Gelmon K, Bontenbal M, et al: Randomized trial of 2 doses of Taxol in metastatic breast cancer: An interim analysis. Proc Am Soc Clin Oncol 12:42, 1993 (abstr)
27. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
28. Rowinsky EK, Eisenhauer EA, Chaundhry V, et al: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15, 1993
29. Verweij J, Clavel M, Chevallier B: Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind. Ann Oncol 5:495-505, 1994
30. Schrijvers D, Wanders J, Dirix L, et al: Coping with toxicities of docetaxel (Taxotere, docetaxel). Ann Oncol 4:610-611, 1993
31. Eisenhauer EA, Lu F, Muldal A, et al: Predictors and treatment of docetaxel toxic effects. Eighth NCI-EORTC Symposium with docetaxel on new drugs in cancer therapy. Ann Oncol 5:202, 1994 (suppl, abstr 506)
32. Valero V, Walters R, Theriault R, et al: Phase II study of docetaxel (Taxotere) in anthracycline refractory metastatic breast cancer. Proc Am Soc Clin Oncol 13:1636, 1994 (abstr)
33. Galindo E, Kavanagh J, Fossella F, et al: Docetaxel (Taxotere) toxicities: Analysis of a single institution experience of 168 patients (623 courses). Proc Am Soc Clin Oncol 13:452, 1994 (abstr)
34. Oulid Aissa D, Behar A, Spielmann M, et al: Management of fluid retention syndrome in patients treated with Taxotere: Effect of premedication. Proc Am Soc Clin Oncol 13:1614, 1994 (abstr)
35. Dieras V, Fumoleau P, Chevallier B, et al: Second EORTC Clinical Screening Group (CSG) phase II trial of Taxotere (docetaxel) as first line chemotherapy (CT) in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 13:115, 1994 (abstr)